Expression Profile of MicroRNAs in Young Stroke Patients by Tan, Kay Sin et al.
Expression Profile of MicroRNAs in Young Stroke Patients
Kay Sin Tan
1, Arunmozhiarasi Armugam
2, Sugunavathi Sepramaniam
2, Kai Ying Lim
2, Karolina Dwi
Setyowati
2, Chee Woon Wang
1, Kandiah Jeyaseelan
2*
1Departments of Medicine and Molecular Medicine, University of Malaya, Kuala Lumpur, Malaysia, 2Department of Biochemistry, Yong Loo Lin School of Medicine,
National University of Singapore, Singapore, Singapore
Abstract
Background: The methods currently available for diagnosis and prognosis of cerebral ischaemia still require further
improvements. Micro-RNAs (small non-coding RNAs) have been recently reported as useful biomarkers in diseases such as
cancer and diabetes. We therefore carried out microRNA (miRNA) profiling from peripheral blood to detect and identify
characteristic patterns in ischaemic stroke.
Methods/Principal Findings: The ischaemic stroke patients aged between 18–49 years, characterized based on World
Health Organization clinical criteria were further classified according to TOAST classification, a) Large-vessel atherosclerosis
[n=8] b) Small-vessel disease [n=3] c) Cardioembolism [n=5] d) Undetermined cause [n=3]. The patients’ functional status
at the time of blood sampling (at the outpatient clinics) was evaluated with the modified Rankin Scale (mRS). Blood samples
from normal (n=5) individuals were used as controls. Total RNA extracted from whole blood was subjected to miroRNA
profiling and real-time PCR analysis. miRNAs that are implicated in the endothelial/vascular function, erythropoiesis,
angiogenesis and neural function showed differential expression profile as compared to the normal control. Interestingly,
miRNAs that are involved in hypoxic conditions have also been found in our miRNA profiles.
Conclusion: We demonstrate that the peripheral blood miRNAs and their profiles can be developed as biomarkers in
diagnosis and prognosis of cerebral ischaemic stroke. The dysregulated miRNAs have been detectable even after several
months from the onset of stroke in what is usually regarded as neurologically stable patients.
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Introduction
MicroRNAs (miRNAs) are tiny (,19–23 nt) non-coding RNA
molecules that are currently being recognized as endogenous
physiological regulators of gene expression. These small RNAs are
capable of controlling gene expression either by repression of
translation/transcription (RNAi)[1] or by activation (RNAa) of
transcription[2]. MiRNAs are also known to play important roles
in many physiological and pathological processes, including
tumorigenesis[3], proliferation[4], hematopoiesis[5], metabo-
lism[6], immune function[7], epigenetics and neurodegenerative
diseases[8]. MiRNAs have also been found to be useful in
identifying the etiology of lymphoma[9] and progression of certain
neurological diseases[10]. However, only few reports are available
on the roles of miRNAs in cerebral ischemia/brain injury in
animal models[11–13]. Using rodent models for ischemic stroke
(MCAo), we have shown that miRNAs are temporally regulated
during progression/reperfusion of cerebral ischemia and miRNAs
in total blood could be used as diagnostic markers. Similarly, in
traumatic brain injury (murine model) temporal regulation of
miRNA expression observed has been correlated to several
biological processes underlying the brain injury[12]. Moreover
Chen et al[14] have demonstrated that serum/plasma miRNAs
derived from various tissues/organs are stable and resistant to
nuclease digestion. Expression levels of miRNAs in blood have
been found to be reproducible and indicative of the disease
state[14]. Thus we propose that specific signatures of blood
miRNA could be obtained from total blood samples and can be
used in the identification of biomarkers for diagnosis, prognosis or
even etiology of a disease. In this study, using the blood samples
obtained from young ischemic stroke patients (18 to 49 years) we
have shown that besides the disease progression, the stroke subtype
could also be identified via the miRNA profiles.
Results
MiRNA Profiles
The profiles demonstrate that microRNAs can be detected in
total peripheral blood in human as was demonstrated for rat’s
blood[11]. The heat maps generated also indicate that the
microRNAs are differentially expressed between normal and
stroke subjects (Figure 1a). Differential expression of miRNAs
could also be observed among the samples representing different
stroke subtypes. Many miRNAs that are poorly expressed in
normal subjects have been found to be highly expressed in stroke
samples. All the miRNAs that are statisticlly significant and
PLoS ONE | www.plosone.org 1 November 2009 | Volume 4 | Issue 11 | e7689Figure 1. microRNA profile data. ( (a) ) MicroRNA profiles: For normal control, all stroke samples pooled (stroke, n=19), small artery (SA, n=3), large
artery (LA, n=8) and cardioembolic (CEmb, n=5) stroke. The hierachical clustering was carried out for both the samples as well as the miRNAs. The
average signal intensities for each significantly expressed miRNA (one way ANOVA, p value,0.05) was log10 transformed and the values have been
used for the construction the tree. (b). Principal Component Analysis (PCA) were carried out on the same set of data. The hierachical clustering and
PCA were constructed using the using the TM4 software [29].
doi:10.1371/journal.pone.0007689.g001
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Stem-loop real-time PCR results on selected miRNAs (miR-16,
126, -144, -21, -223 and -320a; Table 1) also have been found to
be consistent with the expression patterns observed by miRNA
profiling.
Hierachical clustering (Figure 1a) showed two main branches.
All stroke samples that have been pooled together, (n=19) and
designated as ‘‘stroke’’ and the small artery stroke sample (SA;
n=3) formed one cluster. The large artery stroke samples (LA;
n=8) and cardioembolic stroke samples (CEmb; n=5) formed
another cluster. The control samples (control; n=5) were found to
form a separate cluster from that of LA and CEmb. Principal
component analysis (PCA; Figure 1b) showed that among the five
sample groups (control, stroke, LA, CEmb and SA), LA was
clustered with CEmb and SA was clustered with Stroke as was
seen with hierachical clustering. Despite these similarities, the
samples remained significantly different from each other.
Expression of MiRNAs that Are Significantly Affected by
Stroke
Among the 836 microRNAs (mirBase version 11.0; Sanger
Database), present on the array chip, 157 microRNAs have been
found to be differentially regulated (one way ANOVA, p,0.05)
across stroke samples and the subtypes (LA, SA, CEmb, UND;
Table S1). Among the 157 microRNAs identified for stroke
samples (n=19), 138 miRNAs have been found to be highly
expressed (upregulated; fold change .1.0) and 19 miRNAs have
been found to be poorly expressed (downregulated; fold change
,1.0). Within these 19 poorly expressed microRNAs, we could
observe 8 miRNAs (hsa-let-7f, miR-126, -1259, -142-3p, -15b,
-186, -519e, -768-5p) to be poorly expressed across the three
subtypes of stroke (LA, SA and CEmb) that were examined.
Similarly, among the highly expressed (138) miRNAs that were
observed for stroke, 17 microRNAs (hsa-let-7e, miR-1184, -1246,
-1261, -1275, -1285, -1290, -181a, -25*, -513a-5p, -550, -602,
-665, -891a, -933, -939, -923) can also be identified as highly
expressed in the subtypes (Table 2).
MiRNA Patterns in Small Artery (SA) vs Large Artery (LA)
Stroke
The miRNA profile of small artery (SA) stroke samples showed a
distinctly different pattern from that of the large artery (LA) strokes
samples (Figure 1a). Seventy nine (79) miRNAs could be identified
as differentially regulated among these two subtypes (Table 3). Of
these, in the small artery (SA) stroke samples, 77 constituted the
highly expressed (fold change .1) microRNAs (Table 3). Seven of
them (hsa-let-7d*, miR-16, -26b, -150, -374a, -320c, -652) were
found to be expressed at the basal level (fold change 1.0–1.04) and
one (miR-768-3p) was found to be poorly expressed (fold change
0.9260.06). An opposite trend in expression was observed in the
large artery (LA) stroke samples. Of the total 79 miRNAs, 77 were
downregulated and one (miR-939) was undetectable and the other
(miR-768-3p) was upregulated. It is interesting to note that the
microRNAsthat have been found to be upregulated inLAhavealso
Table 1. Validation of microarray data.
microRNA microarray data (fold change)
miRNA Stroke
Stroke
mRS,2
Stroke
mRS.2L A
LA
mRS,2
LA
mRS.2 CEmb
CEmb
mRS,2
CEmb
mRS.2
SA
mRS,2
UND
mRS,2
hsa-miR-
126
0.7960.02 0.3160.01 0.7560.05 0.5060.07 0.1660.02 0.8460.08 0.3760.03 0.2060.01 0.5360.05 0.7160.05 0.9260.14
hsa-miR-
144
1.3560.08 0.8760.07 1.6160.07 0.8560.02 0.4260.06 1.2860.01 1.1760.05 0.6560.09 1.7060.03 1.7060.03 1.5760.00
hsa-miR-16 1.0260.02 0.6260.08 1.0360.03 0.6760.02 0.3060.03 1.0360.03 0.7460.02 0.4660.03 1.0260.04 1.0360.03 1.0160.04
hsa-miR-21 1.3460.14 0.5860.15 1.2860.15 0.7560.00 0.1760.17 1.3360.02 0.7560.12 0.3560.12 1.1560.12 1.7260.15 1.7960.20
hsa-miR-
223
1.4460.04 0.8860.08 1.4260.02 0.9360.06 0.2560.01 1.6160.08 0.5760.03 0.3560.06 0.8060.02 1.7160.04 1.7260.11
hsa-miR-
320a
2.0760.11 1.1960.10 2.6060.10 1.1060.01 0.7060.11 1.5060.03 2.1860.05 1.5760.09 2.8060.03 1.7560.12 1.3560.11
microarray results validated by stem-loop real-time PCR (relative expression)
miRNA Stroke
Stroke
mRS,2
Stroke
mRS.2L A
LA
mRS,2
LA
mRS.2 CEmb
CEmb
mRS,2
CEmb
mRS.2
SA
mRS,2
UND
mRS,2
hsa-miR-
126
0.8160.06 0.4560.02 1.1160.02 0.8560.02 0.3560.05 1.0560.03 0.5460.09 0.3260.08 0.8260.05 0.9460.08 1.1860.05
hsa-miR-
144
2.4660.08 1.5360.04 2.7360.10 1.5560.01 0.7860.09 2.5360.06 2.0960.08 1.2460.05 3.1460.03 3.4360.04 1.9660.02
hsa-miR-16 1.8660.06 1.0960.03 1.6960.05 1.1760.02 0.5360.01 1.6460.05 1.2760.01 0.7360.07 1.7560.02 1.8660.07 1.5960.03
hsa-miR-21 2.4060.07 1.0760.01 2.2760.08 1.3560.01 0.3260.01 2.2960.00 1.2960.03 0.6860.08 1.9560.01 3.1660.04 3.4560.07
hsa-miR-
223
2.0160.02 1.0160.02 2.4760.06 1.2360.03 0.4760.02 2.4260.05 0.7860.00 0.5860.03 1.360.01 2.5260.03 2.7660.05
hsa-miR-
320a
3.6060.07 2.0460.00 4.2160.06 1.8360.01 1.3060.06 2.5860.04 3.0960.04 2.5660.06 4.8460.04 3.1660.06 2.4060.05
Six microRNAs were randomly selected from the array results and their expression level was quantitated using the stem-loop PCR. The relative expression values are
shown with 6SEM. Stroke (all stroke cases, n=19; StrokemRS,2 (n=15), StrokemRS.2 (n=4); Small artery stroke (SA) mRS,2 (n=3), Large artery stroke (LA; n=8)
[LAmRS,2 (n=6), LAmRS.2 (n=2)] and Cardioembolic stroke (CEmb; n=5) [mRS,2 (n=3), mRS.2 (n=2)], stroke due to undetermined cause (UND, n=3). Sample
identification is as listed in Table S1.
doi:10.1371/journal.pone.0007689.t001
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the highly upregulated (fold change.1.5) miRNAs, 7 miRNAs
(hsa-miR-130b, -29b, -301a, -339-5p, -532-5p, -634, 886-5p)
showed more than 2 fold change in SA samples.
Undetermined Stroke vs Stroke Subtypes
Hierachical clustering analysis on the microRNA profiles
observed among the different subtypes (Figure 2a) showed that
undetermined stroke samples (n=3, mRS,2) resembled the
profile of small artery stroke (SA, n=3, mRS,2). PCA (Figure 2b)
also showed that the SA and UND sample are closely related.
Hence it is plausible to assume that the samples with an
undetermined etiology could have resulted from small artery
stroke.
Good vs Poor Stroke Outcome
Principal component analysis of the stroke samples based on the
clinical outcome (mRS) showed that all samples of good outcome
(mRS,2; stroke, LA and CEmb) have been found to cluster along
same panel with almost consistent distant between them. The poor
outcome (mRS.2) stroke samples have been found to cluster away
from the samples with good outcome (mRS,2; Figure 2b). The
SA samples with good outcome (mRS,2) have been found to
exhibit a unique pattern to that of LA and CEmb cases with good
outcome (mRS,2). The reason for this observation is unknown.
Similar observation has been made with hierachical clustering of
the samples and miRNAs (Figure 2a).
Discussion
Protein biomarkers from blood (serum/plasma) have been
widely used over the years for clinical diagnosis and prognosis.
Recently, circulating nucleic acids in peripheral blood samples
have proven to be useful biomarkers in the diagnosis of stroke
pathogenesis[15]. Cardioembolic and the large-vessel atheroscle-
rotic stroke have been distinguished based on mRNA expression
profiles[16]. miRNA-induced gene expression has also been shown
to contribute extensively to the disease phenotype[17]. The
apparent roles of miRNAs in diseases have led many researchers
to probe into the molecular mechanisms underlying pathogenesis
as well as to develop novel diagnostic and therapeutic agents[18].
We observed that the miRNAs are stably expressed and in
circulation even after several months from the onset of stroke. This
correlated with the observation by Chen et al[14] that miRNAs (in
serum) are stable, resistant to nuclease digestion and almost
consistent among individuals.
Table 2. microRNAs that show similar expression among the various stroke samples.
miRNA Stroke
Stroke
mRS,2
Stroke
mRS.2L A
LA
mRS,2
LA
mRS.2 CEmb
Cemb
mRS,2
Cemb
mRS.2 SA UND
hsa-let-7e 3.0260.11 2.290.00 3.6260.09 3.2060.02 3.1260.04 3.0360.09 3.8360.00 3.7960.05 3.8760.04 2.6060.05 1.5660.00
hsa-let-7f 0.6960.05 0.3060.06 0.7060.07 0.4560.08 0.1560.07 0.7560.08 0.3760.09 0.2060.09 0.5460.10 0.6060.08 0.9760.07
hsa-miR-1184 3.0960.04 1.7860.08 2.1860.02 1.4360.03 1.1960.08 1.5360.02 1.9260.06 1.3360.05 2.5160.11 3.1160.01 2.2160.06
hsa-miR-1246 1.6660.00 1.4460.01 1.6860.00 1.7860.05 2.2560.09 1.2960.03 2.0960.05 2.0760.00 2.1060.09 1.2960.05 1.6760.08
hsa-miR-1259 0.7160.06 0.1760.18 0.9260.05 0.7460.08 0.6260.07 0.8560.19 0.5460.20 0.2260.92 0.7860.02 0.3460.03 0.6360.01
hsa-miR-126 0.7960.02 0.3160.01 0.7560.05 0.5060.07 0.1660.02 0.8460.08 0.3760.03 0.2060.01 0.5360.05 0.7160.05 0.9260.14
hsa-miR-1261 3.9560.07 1.8160.04 5.5260.05 1.8260.06 1.5160.06 1.8360.06 4.0260.02 1.3560.21 6.6560.07 2.8760.07 3.0860.08
hsa-miR-1275 3.0660.04 2.2760.02 3.0160.02 1.5160.05 1.6360.03 1.2460.07 2.7160.06 2.5160.04 2.9160.08 2.3260.04 3.3660.03
hsa-miR-1285 1.8760.06 1.2260.06 1.6860.07 1.3460.01 1.5460.00 1.1460.03 1.3760.02 1.0460.02 1.7060.03 1.3060.04 1.3960.01
hsa-miR-1290 2.0160.03 1.7060.04 1.9860.02 2.1460.01 2.7160.01 1.5760.05 2.2760.05 2.2060.05 2.3360.05 1.3760.01 2.2760.01
hsa-miR-142-3p 0.5960.02 0.2860.01 0.6960.01 0.4360.08 0.1860.03 0.6860.10 0.3760.03 0.1560.03 0.6060.05 0.7060.01 0.8660.06
hsa-miR-15b 0.9460.01 0.5360.05 0.9360.07 0.5960.04 0.4860.09 0.7060.00 0.7060.08 0.5960.06 0.8160.09 0.6560.06 0.6660.11
hsa-miR-181a 1.6460.04 1.5660.06 1.7460.06 1.1460.04 1.0660.02 1.2260.05 1.8960.03 1.6460.02 2.1560.04 1.7660.03 2.2660.06
hsa-miR-186 0.8460.03 0.4860.03 0.8160.01 0.4460.03 0.2160.06 0.6860.02 0.6760.07 0.5260.00 0.8160.11 0.8360.04 0.7460.12
hsa-miR-25* 1.6460.07 1.2160.04 1.9160.03 1.4860.09 1.2760.07 1.6660.21 2.1860.20 1.2660.04 3.0760.26 1.6260.05 1.4560.17
hsa-miR-513a-5p 2.0460.00 1.3060.03 2.0160.02 1.2960.05 1.3060.00 1.2860.09 1.8960.01 1.6260.00 2.1660.01 1.5860.00 1.7660.01
hsa-miR-519e 0.6360.05 0.5960.00 0.9060.02 0.7860.16 0.5860.06 0.9760.21 0.4360.03 0.3060.07 0.5760.00 0.9360.06 0.7660.08
hsa-miR-550 1.8160.09 1.0660.10 1.9160.09 1.3260.04 1.2960.12 1.3360.04 1.5260.12 1.0960.12 1.9560.13 1.4960.10 1.3660.15
hsa-miR-602 2.4860.03 1.8360.08 3.0660.03 1.4760.01 1.3760.08 1.5660.10 2.5760.06 1.9460.02 3.1960.08 2.4560.10 2.4660.04
hsa-miR-665 3.0260.10 1.8160.10 3.2660.10 2.3360.03 2.2660.07 2.3960.11 2.6760.02 2.3960.04 2.9660.01 2.0560.06 1.5760.05
hsa-miR-768-5p 0.9760.06 0.4260.09 1.0560.10 0.7560.01 0.6760.09 0.8460.05 0.6760.14 0.4260.06 0.9360.18 0.5260.08 0.8060.17
hsa-miR-891a 2.4860.12 1.8560.05 2.1060.17 1.6160.17 2.0060.15 1.4260.19 1.6160.18 1.1260.13 2.0960.21 3.5560.14 1.7460.19
hsa-miR-923 2.4160.02 2.1260.06 2.3460.02 2.0860.10 2.4260.06 1.5660.17 2.6860.02 2.8560.03 2.5060.07 1.5860.01 2.8360.05
hsa-miR-933 1.8360.02 1.3260.01 1.7560.00 1.3160.00 1.1760.00 1.4660.00 1.6360.00 1.3360.03 1.9260.02 1.8460.03 1.4460.02
hsa-miR-939 2.1560.02 1.2960.02 2.4760.06 - 1.1260.02 1.7160.07 1.9660.03 1.4560.00 2.4760.05 1.5960.01 1.6360.04
Value expressed as fold change 6SEM of each sample is based on pooled sample of individual stroke subtype. The signal log ratio (stroke/normal control) of the
averaged signal values were log2 transformed to obtain the fold change. mRS: modified Rankin Score; LA: large artery stroke; SA: small artery stroke; CEmb:
cardioembolic stroke; UND: undetermined cause.
doi:10.1371/journal.pone.0007689.t002
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Patients
Distinct patterns of miRNAs indicative of the outcome of
cerebral ischaemia have been observed. It is noteworthy that
several miRNAs instead of a single miRNA, show changes during
the progression of a disease. Another interesting observation is that
more microRNAs are downregulated in all good outcome
(mRS,2) stroke samples compared to normal controls, irrespec-
tive of subtype of stroke (Table S1).
miRNAs that are involved in endothelial function and
angiogenesis (hsa-let-7f, miR-130a, -150, -17, -19a, -19b, -20a,
-222 and -378)[18], vascular remodeling (miR-21, -126, -150),
regulation of hematopoeisis (miR-223) as well as immune response
(miR-20a, -17-92, -101, -150, -106a, -181a and -223)[7] have been
found to be differentially regulated under ischemic conditions.
Similarly, miRNAs that are expressed in hypoxic conditions (miR-
23, -24, -26, -103, -107, -181)[19] have also been observed.
Furthermore, the miRNAs that showed aberrant expression in
cardiomyocyte hypertrophy and/or cardiac ischemia/reperfusion
(miR-15, -16, -21, -23a, -29, -30a, -150 and -195)[20,21] have also
been detected in our profiling data.
The microRNAs, let-7a, let-7c, miR-16, -19b, -23a, -103,
-106b, -185, -191, -320 and -451 that were present in both the
blood and brain samples of rodent stroke (MCAo)[11] model have
also been detected in the human blood samples used in this study.
Interestingly, these groups of miRNAs are also known to
participate in the regulation of angiogenesis (miR-320), hemato-
poetic process (miR-451), lymphocyte differentiation and prolifer-
ation (miR-103), cardiovascular function (miR-23a, -103, -451),
metabolic processes (miR-451 and -320), immune response (miR-
16) and hypoxic conditions (miR-23a, -103, -320). Microarray-
based expression profiles in cancer cell lines revealed that a specific
spectrum of microRNAs (including miR-23, -24, -26, -27, -103,
-107, -181 and -210) has been induced in response to occlusion.
Of these, miR-26, -107, and -210 decrease pro-apoptotic signaling
in a hypoxic environment, thus suggesting a role in cell
proliferation[19].
Upregulated miR-320 was associated with impaired angiogen-
esis in myocardial microvascular endothelial cells (MMVEC) of
type 2 diabetic Goto-Kakizaki (GK) rats[22]. miR-320 has been
observed to be marginally downregulated (fold change ,1-1.5) in
all stroke patients especially with good outcome (mRS,2). The
downregulation of miR-320 could also lead to anti-apoptotic
processes[23] that could be useful in restoration of normal cell or
endovascular activities. Hence it could be predictive of a favorable
outcome via activation of angiogenesis in stroke patients.
Table 3. miRNA expression pattern in large artery (LA) and small artery (SA) stroke.
hsa-miRNA Stroke LA SA hsa-miRNA Stroke LA SA hsa-miRNA Stroke LA SA
let-7b 1.23 0.51 1.13 miR-18b 1.46 0.87 1.90 miR-320b 1.52 0.86 1.26
let-7c 1.18 0.55 1.10 miR-191 1.47 0.70 1.34 miR-320c 1.39 0.78 1.04
let-7d* 1.59 0.77 1.02 miR-194 1.79 0.87 1.64 miR-320d 1.56 0.87 1.28
miR-101 1.54 0.83 1.98 miR-195 1.06 0.45 1.32 miR-331-3p 1.44 0.89 1.15
miR-103 1.31 0.84 1.64 miR-19a 1.41 0.82 1.23 miR-339-5p 2.26 0.98 2.08
miR-106a 1.49 0.84 1.77 miR-19b 1.65 0.88 1.62 miR-361-5p 1.58 0.88 1.80
miR-106b 1.42 0.77 1.77 miR-20b 1.29 0.69 1.37 miR-362-5p 1.78 0.75 1.73
miR-106b* 1.42 0.80 1.37 miR-21 1.34 0.75 1.72 miR-363 1.24 0.67 1.10
miR-107 1.17 0.76 1.37 miR-222 1.31 0.67 1.70 miR-374a 0.93 0.66 1.00
miR-1265 1.36 0.99 1.13 miR-223 1.44 0.93 1.71 miR-378 1.43 0.63 1.22
miR-130a 1.56 0.99 1.70 miR-23a 1.63 0.86 1.78 miR-425 1.29 0.82 1.19
miR-130b 1.78 0.89 2.33 miR-23b 1.37 0.67 1.39 miR-487b 1.27 0.76 1.62
miR-138-1* 1.20 0.93 1.43 miR-24 1.23 0.58 1.17 miR-501-5p 1.52 0.74 1.20
miR-140-3p 1.29 0.72 1.12 miR-24-1* 1.19 0.81 1.24 miR-532-5p 1.65 0.66 2.10
miR-142-5p 1.42 0.80 1.24 miR-25 1.24 0.56 1.23 miR-550* 1.37 0.85 1.27
miR-144 1.35 0.85 1.70 miR-26a 1.17 0.58 1.28 miR-551b 1.12 0.89 1.05
miR-144* 0.69 0.60 1.07 miR-26b 0.97 0.57 1.00 miR-628-3p 1.67 0.96 1.33
miR-150 2.22 0.61 1.01 miR-29a 1.40 0.75 1.34 miR-634 1.70 0.94 2.72
miR-151-5p 1.47 0.75 1.56 miR-29b 1.58 0.84 2.03 miR-652 1.14 0.71 1.01
miR-15a 1.07 0.63 1.21 miR-300 1.28 0.56 1.31 miR-720 1.63 0.96 1.27
miR-16 1.02 0.67 1.03 miR-301a 1.56 0.97 2.05 miR-744 1.84 0.98 1.29
miR-16-2* 1.42 0.84 1.38 miR-30a 1.30 0.72 1.33 miR-765 1.33 0.91 1.17
miR-17 1.26 0.72 1.48 miR-30b 0.98 0.59 1.07 miR-768-3p 1.49 1.13 0.92
miR-17* 2.02 0.73 1.63 miR-30c 1.29 0.66 1.30 miR-886-5p 2.10 0.82 2.36
miR-182 1.35 0.48 1.37 miR-30d 1.48 0.77 1.29 miR-93 1.29 0.70 1.33
miR-183 1.32 0.54 1.22 miR-30e 1.16 0.71 1.21 miR-939 2.15 - 1.59
miR-185 1.78 0.93 1.54
microRNAs that shows opposite expression between the two subtypes (LA & SA) are listed. miRNAs that are expressed more than 2 fold change are in bold letters.
6SEM values are as listed in Table S1.
doi:10.1371/journal.pone.0007689.t003
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PLoS ONE | www.plosone.org 5 November 2009 | Volume 4 | Issue 11 | e7689Figure 2. MicroRNA profiles for the stroke subtypes based on their mRS scores. (a) The PCA analysis carried out on the pooled stroke
samples. (b) Hierachical clustering was carried out for both the samples as well as the miRNAs as described. (Stroke mRS,2 (n=15), Stroke mRS.2
(n=4); Small artery (SA) mRS,2 (n=3), Large artery (LA) mRS,2 (n=6), Large artery (LA) mRS.2 (n=2) and Cardioembolic (CEmb) mRS,2 (n=3),
Cardioembolic (CEmb) mRS.2 (n=2) and undetermined cause (UND) mRS,2 (n=3).
doi:10.1371/journal.pone.0007689.g002
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CEmb, mRS.2. Similar observations were made in MCAo rat
models[11].
Among the upregulated miRNAs in poor outcome (mRS.2)
large artery and cardioembolic stroke, miR-103 and miR-29 have
some significance. MiR-103 has been reported to regulate energy
metabolism[6] while miR-29 regulates insulin resistance[24].
Thus, indicating their importance in energy utilization and
production. Dysregulation of miR-29 has also been demonstrated
in myocardial infarction[21].
We have also observed that subtypes of stroke could be
predicted using the microRNA profiling. The 132 microRNAs
listed in Table S2 could be useful in the prediction of the cause of
stroke. These microRNAs show differential regulation (fold
change) among the different subtypes. Sucharov et al[25] have
shown that miR-125b is upregulated in idiopathic cardiomyo-
pathic condition while the miR-150 is down regulated in both
ischemic failing heart as well as in idiopathic cardiomyopathic
conditions. Ischemic failing heart showed an upregulation for
miR-197, miR-20a and miR-26b[25]. We observed that the
expression of miR-150 was marginally higher, (fold change
1.1660.03) for CEmb (mRS.2). However, the expression is
lower in the mRS,2 conditions for both LA and CEmb samples
(fold change 0.560.21 and 0.5260.26 respectively). The expres-
sion of miR-26b was lowest in mRS,2 conditions for both LA and
CEmb (fold change 0.1960.23 and 0.2860.20 respectively).
Further comparison of the individual sample profiles for C, E
and F [LA1 (C) & LA2 (E); mRS=2) and LA3 (F; mRS=3); Table
S5b] with the miRNA profiles of pooled samples miRNA profile
showed that 72 miRNAs in the individual samples are specific to
stroke (Table S3). Of these, 33 microRNAs were found to be
expressed at either .2o r,0.5 fold change (bold font in Table 4)
in the individual stroke samples. Among the highly upregulated
microRNAs, the expression of miR-101, -106b, -130a, -144, -18a,
-18b, -19a, -19b, -194, -22, -22, -29b, -29c and -363 were the
highest for LA (mRS=3) stroke sample and correlated to the
profile observed for LA mRS.2. The expression value for hsa-let-
7e, -149*, -484, -638, -652, -768-3p, and -923 were lowest in the
LA (mRS=3) sample. Interestingly, the expression of most of the
let-7 family members (let-7b, -7c, -7d, -7f, -7g and -7i) were not
altered (fold change ,1.0) among all the large artery stroke
samples.
MiRNA Targets and Processes
Majority of the microRNAs that have been detected in the
blood appear to be of cardiovascular/vascular, hematopoietic
(hsa-let-7 family, miR-15, -16, -181a, -223)[5] or erythropoietic
(miR-24, -221, -222, -320)[26] origin (Table 4). The differentially
regulated miRs appear to be involved in angiogenic (pro-
angiogenic: miR-130a, -378, -17–92 cluster, let-7f; anti-angiogen-
ic: miR-15, -16, -20a, -20b, -222)[18], proliferative or vascular
inflammatory functions (miR-21, -126) as well as hypoxic
conditions (miR-23, -24, -26, -103, -107, -181)[19]. MicroRNAs
that have been implicated in cardiovascular disease have also been
found in the blood of our stroke patients. Key biological pathways
that are affected by the differentially regulated microRNAs (Table
S4) include MAPK signaling, TGFb signaling, Wnt signaling and
Focal Adhesion pathways. Presumably, these pathways are
involved in important regulatory processes that lead to restoration
and repair mechanisms.
Our analysis of the miRNA profiling has shown that the
regulation of hypoxia, angiogenesis and erythropoiesis/hemato-
poiesis related processes are indeed the key events that occur
during stroke recovery. We have shown that miRNAs could be
used to differentiate cardioembolic, large artery and small artery
strokes from each other. We have also shown that miRNA
profiling could form an additional tool for the clinicians to
determine the outcome of stroke.
Materials and Methods
Patient Selection and Blood Collection
Ethics Statement. This study has been approved by the
Medical Ethics Committee of University of Malaya Medical
Centre (UMMC) and the Institutional Review Board (IRB) of the
National University of Singapore (NUS). Written consent was
Table 4. microRNAs and their target biological processes.
Process/Targets microRNA/paralogs
Up regulated in this stroke study
Down regulated in
this stroke study
Angiogenesis
18 miR-19b, -130a, -15a,-16, -222, -320
Hematopoietic regulation
5 miR-16, -24, -30c, -106b, -223,
Immune response
7 miR-15a, -16, -24, -29a, -93, -181a, -223
Lymphocyte regulation (differentiation & proliferation)
7 miR-101, -181a, -16, -24, -22, -103, -30c, let-7c
Cardiac/vascular function
20 miR-23a, -23b, -24, -29a, -29c, -30a,-30c, -30d -103, -222 miR-126
Endothelial cell migration, differentiation and survival
18 miR-126, -222
Metabolic process regulation
6 miR-130a, -29a, -29c, -320
Hypoxia regulation
19 miR-23a, -23b, -24, -103, -93, -181a, -15a, -16, -101, -126, -320, let-7c, let-7e, miR-7, let-7a
Traumatic brain Injury (mouse brain)
12 miR-103, -130a, -185, -191, -19b, -22, -222, -223, -23a, -23b, -30c, -320, -652, -744
Stroke model (blood of rat-MCAo model)
11 let-7c, miR-103, -106b, -16, -185, -191, -19b, -23a, 320, let-7a
Stroke model (brain of rat MCAo model)
11,13 let-7c, let-7d*, let-7e, miR-103, -126, -130a, -16, -181a, -185, -191, -222, -223, -23a,
-23b, -24, -30c, -324-5p, -320,-29a, -29c, -7
let-7a
The biological processes that are affected by the microRNAs that are differentially expressed in the stroke samples have been analysed. List presented is based on
published data.
doi:10.1371/journal.pone.0007689.t004
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hospital database and used for research.
Clinical Methodology. Nineteen (Asian) stroke patients
between the ages of 18 to 49 among those admitted via the
neurology service at the University of Malaya Medical Centre (a
major 900 bed teaching hospital serving a population of about
800,000) have been selected for the study. The study protocol
included a standard neurological evaluation with subsequent
review and follow up as out patients. In our study, we have utilized
blood samples collected from stroke patients within 6–18 months
in time scale from the index stroke. Ischaemic stroke was
confirmed either with CT or MRI of the brain. Demographic
data, medical history and conventional vascular risk factors were
recorded in a standardized computerized database and abstracted
from the medical records. Risk factors, if any, were defined in the
following manner. Hypertension: BP above 140/90 mm Hg,
Dyslipidemia: total cholesterol level of $6.7 mmol/l, triglyceride
levels $1.8 mmol/l and HDL #1 mmol/l, Diabetes mellitus:
elevated fasting blood glucose .6.1 mmol/l or HbA1c $7%.
Smokers: who smoked $10 cigarettes per day for more than 1
year, Significant alcohol consumption: as $30 g of ethanol per
day. Current medications (if any) were also recorded. Modified
Rankin Score (mRS) [27] was evaluated at the time of blood
sampling. Further diagnostic work-up included chest radiography,
ECG, routine blood tests such as fasting lipid profile, fasting
glucose and HbA1c. When routine stroke investigations were
normal or negative, thrombophilia screen and detailed
immunologic studies (anti-nuclear, anti-DNA and anti-ENA
antibodies) were performed. Stroke events were classified when
the patient was completely evaluated with the aetiology identified.
Overall, the basis of the above classifications was based on clinical,
imaging, routine and optional tests. Accordingly, the TOAST
classification was applied. The stroke subjects used: a) Large-vessel
atherosclerosis (n=8); b) Small-vessel disease (n=3); c)
Cardioembolism (n=5); d) Undetermined cause (n=3). A total
of 5 normal samples (n=5) were also included as controls (Table
S5a & S5b).
Extraction of Micro RNAs from Blood Sample
Total RNA (+small RNA) was extracted from the blood samples
using the Ribopure
TM -Blood RNA isolation kit (Ambion, Austin,
TX). The concentration of RNA was determined by a NanoDrop
ND-1000 Spectrophotometer (Rockland, DE). The quality of
RNAs was determined using denaturing gels (15% polyacrylamide
and 1% agarose as needed)[11].
MiRNA Stem-Loop Real-Time PCR
Quantitation of miRNAs was carried out using TaqMan Real-
Time PCR[11]. Briefly, 10 ng of template RNA was reverse
transcribed (in 15 ml) using stem-loop primer. For the PCR
reaction, 1.33 ml (0.891 ng) of RT-product was used. PCR was
carried out using the Applied Biosystems 7000 Sequence
Detection System. Both RT- and PCR-reactions were performed
in triplicate, in 3 separate experiments. miRNAs were considered
as present when CT-values (threshold cycle) were lower than 30.
The 18S rRNA was used as the housekeeping gene.
mParaflo
TM MicroRNA Microarray Assay and Analysis
Total RNA (2–5 mg) was size fractionated using a YM-100
Microcon (Millipore) and the small RNAs (,300 nt) isolated were
39-extended using poly(A) polymerase. Test (pooled or individual
stroke samples) and control samples were tagged at the poly(A) tails
separately. Samples were pooled for all stroke (n=19) [mRS,2
(n=15), mRS.2 (n=4)], large artery (LA) stroke (n=8) [mRS,2
(n=6), mRS.2 (n=2)]; Cardioembolic (CEmb) stroke (n=5)
[mRS,2 (n=3), mRS.2 (n=2)]; Small artery (SA) stroke
(mRS,2, n=3) and stroke of undetermined cause (UND,
mRS,2, n=3). Hybridization was performed overnight on a
mParaflo microfluidic chip using a micro-circulation pump (Atactic
Technologies). On the chip, each detection probe consisted of a
chemically modified nucleotide coding segment complementary to
target microRNA (miRBase 10.1 and 11.0, http://microrna.
sanger.ac.uk/sequences/). Hybridization images were scanned
(GenePix 4000B, Molecular Device) and digitized using Array-Pro
image analysis software (Media Cybernetics). Data were analyzed
by first subtracting the background and then normalizing the
signals using a LOWESS filter (Locally-weighted Regression;28].
The signal log ratio and p-values were calculated. Differentially
detected signals were defined as those with less than 0.05 p-values.
Microarray Analysis involved multiple sample analysis including
background subtraction, t-Test/ANOVA analysis, clustering and
principal component analysis. t-Test was performed between
‘‘control’’ and ‘‘test’’ sample groups and t-values were calculated
for each miRNA. p-values were computed from the theoretical
t-distribution. miRNAs with p-values #0.01 were selected for
cluster analysis. The microarray data reported in this manuscript is
described in accordance with MIAME guidelines. The clustering
using hierarchical method was performed with average linkage
and Euclidean distance metric. The clustering and principal
component analysis (PCA) plot was generated using TIGR MeV
(Multiple Experimental Viewer) software[29].
Supporting Information
Table S1 miRNAs that have been detected in the peripheral
blood of stroke patients. Fold Change (?SEM) of statistically
significant (one way ANOVA, p value,0.05). The miRNAs that
are upregulated in stroke (n=19) is marked in red and the
downregulated miRNAs are in green fonts.
Found at: doi:10.1371/journal.pone.0007689.s001 (0.17 MB
PDF)
Table S2 miRNA that showed mixed (up/and/or down)
expression in stroke. Only fold change is shown (refer to Table
S1 for ?SEM). The miRNAs that are upregulated in stroke (n=19)
is marked in red and the downregulated miRNAs are in green
fonts.
Found at: doi:10.1371/journal.pone.0007689.s002 (0.07 MB
PDF)
Table S3 miRNA expression pattern of pooled and individual
large artery stroke samples. Individual samples [LA1&2(mRS=2)
and LA(mRS=3)] miRNA expression values is compared with the
pooled sample miRNA profile of the larger artery stroke. The 72
miRNAs listed here correlated to the total miRNA that are
differentially altered in the stroke sample. The microRNAs that
are expressed in more than 2 fold change are in bold letters.
Found at: doi:10.1371/journal.pone.0007689.s003 (0.04 MB
XLS)
Table S4 miRNAs that are differentially expressed in stroke
patients and the pathways that they possibly regulate. The
miRNA:biological process relationship was predicted using
miRNApath search tool (http://lgmb.fmrp.usp.br/mirnapath/
tools.php and http://diana.cslab.ece.ntua.gr/) [30]. The pathways
that have the largest number of genes affected by the miRNAs and
with the highest [2ln(p-value)] are listed.
Found at: doi:10.1371/journal.pone.0007689.s004 (0.07 MB
DOC)
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comparison and (b) Detailed medication and modified Rankin
Score of young Asian stroke patients selected for the study.
Controls (n=5) included 3 males and 2 females.
Found at: doi:10.1371/journal.pone.0007689.s005 (0.07 MB
DOC)
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